P486: Treatment-emergent COVID-19 infections in ozanimod ulcerative colitis and multiple sclerosis clinical trialsECCO'22Year: 2022
Authors: Ungaro , R.(1);Siegel , C.A.(2);Cree , B.A.C.(3);Selmaj , K.W.(4,6);Ahmad , H.A.(5);Pai , A.(5);Ather , S.(5);Henry , A.(5);Charles , L.(5);Petersen , A.(5);Cheng , C.Y.(5);Afsari , S.(5);Sheffield , J.(5);Vaile , J.(5);Colombel , J.F.(1);
(1)Icahn School of Medicine at Mount Sinai, Gastroenterology, New York, United States;(2)Dartmouth-Hitchcock Medical Center, Gastroenterology, Lebanon, United States;(3)UCSF MS Center, Neurology, San Francisco, United States;(4)Centrum of Neurology, n/a, Lodz, Poland;(5)Bristol Myers Squibb, Department of Immunology and Fibrosis Development, Princeton, United States;(6)University of Warmia & Mazury, Department of Neurology, Olsztyn, Poland;
P487: Surgery due to inflammatory bowel disease during pregnancy: mothers and offspring outcomes (SCAR Study)ECCO'22Year: 2022
Authors: Chaparro, M.(1);Aguas, M.(2);Livne, M.(3);Rivière, P.(4);Bar-Gil Shitrit, A.(5);Myrelid, P.(6);Arroyo, M.(7);Barreiro-de Acosta, M.(8);Bautista, M.(9);Biancone, L.(10);Biron, I.A.(5);Boysen, T.(11);Carpio, D.(12);Castro, B.(13);Dragoni, G.(14);Ellul, P.(15);Holubar, S.D.(16);de Jorge, M.Á.(17);Leo, E.(18);Manceñido, N.(19);Moens, A.(20);Ramírez de la Piscina, P.(21);Ricanek, P.(22);Sebkona, L.(23);Sempere, L.(24);Teich, N.(25);Gisbert, J.P.(1);Julsgaard, M.(26);
(1)Hospital Universitario de La Princesa- Instituto de Investigación Sanitaria Princesa IIS-IP- Universidad Autónoma de Madrid- and Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas CIBERehd, Gastroenterology Unit, Madrid, Spain;(2)Hospital Universitario y Politécnico La Fe and CIBERehd, Gastroenterology Unit, Valencia, Spain;(3)Sheba Medical Center, Gastroenterology Unit, Tel Hashomer, Israel;(4)Bordeaux University Hospitals, Gastroenterology Unit, Bordeaux, France;(5)Shaare Zedek Medical Center, Gastroenterology Unit, Jerusalem, Israel;(6)Linköping University Hospital and Department of Biomedical and Clinical Sciences- Linköping University, Surgery, Linköping, Sweden;(7)Hospital Clínico Universitario Lozano Blesa- CIBERehd and IIS Aragón, Gastroenterology Unit, Zaragoza, Spain;(8)Complejo Hospitalario Universitario de Santiago, Gastroenterology Unit, Santiago de Compostela, Spain;(9)Hospital Joan XXIII, Gastroenterology Unit, Tarragona, Spain;(10)University of Rome “Tor Vergata”, Gastroenterology Unit, Rome, Italy;(11)Hvidovre University Hospital, Gastroenterology Unit, Hvidovre, Denmark;(12)Complexo Hospitalario Universitario de Pontevedra- Instituto de Investigación Sanitaria Galicia Sur, Gastroenterology Unit, Pontevedra, Spain;(13)Hospital Universitario Marqués de Valdecilla and IDIVAL, Gastroenterology Unit, Santander, Spain;(14)Careggi University Hospital, Gastroenterology Unit, Florence, Italy;(15)Mater Dei Hospital, Gastroenterology Unit, Msida, Malta;(16)Cleveland Clinic Foundation, Gastroenterology Unit, Cleveland, United States;(17)Hospital de Cabueñes, Gastroenterology Unit, Gijón, Spain;(18)Hospital Universitario Virgen del Rocío, Gastroenterology Unit, Sevilla, Spain;(19)Hospital Universitario Infanta Sofía, Gastroenterology Unit, San Sebastián de los Reyes, Spain;(20)University hospitals Leuven, Gastroenterology Unit, Leuven, Belgium;(21)Hospital Universitario de Araba sede Txagorritxu y sede Santiago, Gastroenterology Unit, Álava, Spain;(22)Akershus universitetssykehus, Gastroenterology Unit, Ski, Norway;(23)Azieda Opedaliera Pluguiese-Ciaccio, Gastroenterology Unit, Catanzaro, Italy;(24)Hospital General Universitario de Alicante and CIBERehd, Gastroenterology Unit, Alicante, Spain;(25)Practice for internal medicine, Gastroenterology Unit, Leipzig, Germany;(26)Aarhus University Hospital, Gastroenterology Unit, Aarhus, Denmark;on behalf of the ECCO CONFER taskforce
P488: Trends in corticosteroid (CS) use over time and following diagnosis in patients with Inflammatory Bowel Disease (IBD), using IBM® MarketScan®ECCO'22Year: 2022
Authors: Raine, T.(1);Melmed, G.Y.(2);Finney-Hayward , T.(3);Clark, R.(4);Chapman, J.C.(5);Targownik, L.(6);Burisch, J.(7);Olen, O.(8);
(1)Addenbrooke’s Hospital- Cambridge University Hospitals, Department of Gastroenterology, Cambridge, United Kingdom;(2)Cedars-Sinai, Inflammatory Bowel Disease Center, Los Angeles, United States;(3)AbbVie Ltd., Gastroenterology, Maidenhead, United Kingdom;(4)AbbVie Inc., Research and Development, North Chicago, United States;(5)Texas Digestive Disease Consultants, Gastroenterology, Baton Rouge, United States;(6)Mount Sinai Hospital- University of Toronto, Division of Gastroenterology and Hepatology, Toronto- Ontario, Canada;(7)Hvidovre University Hospital, Gastrounit- Medical Division, Hvidovre, Denmark;(8)Karolinska Institutet, Department of Medicine, Stockholm, Sweden;
P489: Temporal trends of colectomy for ulcerative colitis in the multi-drug era; a population based cohort study.ECCO'22Year: 2022
Authors: Jenkinson, P.(1);Plevris, N.(1);Lyons, M.(1);Gros, B.(1);Derikx, L.(1);Constantine-Cooke, N.(1);Jones, G.(1);Lees, C.(1);
(1)Edinburgh IBD Unit, Edinburgh IBD Unit, Edinburgh, United Kingdom;
P490: Patients with inflammatory bowel disease should be vaccinated against pneumococcus and influenza despite immunosuppressive therapyECCO'22Year: 2022
Authors: Dohos, D.(1);Müller, K.E.(1);Sipos, Z.(2);Kiss, S.(2);Dembrovszky, F.(2);Kovács, N.(2);Solymár, M.(2);Erőss, B.(2);Hegyi, P.(2);Sarlós, P.(3);
(1)Heim Pál National Children Hospital, Gastroenterology and Nephrology Department, Budapest, Hungary;(2)University of Pécs, Institute for Translational Medicine, Pécs, Hungary;(3)University of Pécs- Medical School, First Department of Medicine- Division of Gastroenterology, Pécs, Hungary;
P491: Efficacy and safety outcomes of long-term treatment with filgotinib 200 mg among patients with Ulcerative Colitis: An interim analysis of SELECTIONLTEECCO'22Year: 2022
Authors: FeaganSenior Scientific Officer, B.G.(1,2);Matsuoka, K.(3);Rogler, G.(4);Faes, M.(5);Oortwijn, A.(6);de Haas, A.(6);Rudolph, C.(6);Patel, H.(5);Peyrin-Biroulet, L.(7);
(1)Alimentiv, Inc., London- Ontario, Canada;(2)London Health Sciences Centre- Western University, Division of Gastroenterology, London- Ontario, Canada;(3)Toho University Sakura Medical Center, Department of Gastroenterology and Hepatology, Chiba, Japan;(4)University Hospital Zurich- University of Zurich, Department of Gastroenterology and Hepatology, Zurich, Switzerland;(5)Galapagos, Nv, Mechelen, Belgium;(6)Galapagos, Nv, Leiden, The Netherlands;(7)University Hospital of Nancy- University of Lorraine, Department of Gastroenterology, Vandoeuvre-lès-Nancy, France;
P492: A comparison of treatment effects for clinical, endoscopic and histological remission in ulcerative colitis clinical trialsECCO'22Year: 2022
Authors: Sedano, R.(1);Hogan, M.(2);Zou, G.(3);Narula, N.(4);Singh, S.(5);Ma, C.(6);Jairath, V.(7);
(1)Division of Gastroenterology- Department of Medicine- Western University- London- Ontario- Canada/Alimentiv Inc.- London- Ontario- Canada, Department of Medicine- Western University- London- Ontario- Canada, London, Canada;(2)Alimentiv Inc, n/a, London, Canada;(3)Alimentiv Inc., na, London, Canada;(4)Division of Gastroenterology- Department of Medicine Farncombe Family Digestive Health Research Institute- McMaster University- Hamilton- ON- Canada, Division of Gastroenterology- Department of Medicine, Hamilton, Canada;(5)Division of Gastroenterology- University of California San Diego- La Jolla- California- USA, Division of Gastroenterology, San Diego, United States;(6)Division of Gastroenterology & Hepatology- Departments of Medicine and Community Health Sciences- University of Calgary- Calgary- Alberta- Canada, Division of Gastroenterology & Hepatology- Departments of Medicine and Community Health Sciences-, Calgary, Canada;(7)Western University / Alimentiv Inc, Division of Gastroenterology- Department of Medicine- Department of Epidemiology and Biostatistics, London, Canada;
P493: The synthetic glycan KB295 optimises microbiome composition and function in ulcerative colitis: Results from a proof of principle human studyECCO'22Year: 2022
Authors: Meisner, J.(1);Miller , K.(1);Lee, J.(2);Jose, A.(2);Giuggio, M.(3);McComb , M.(1);Humphries, E.(3);Rosini, M.(4);Wingertzahn, M.(5);Shanahan, F.(6);E.T. van Hylckama Vlieg, J.(7);Dowling , M.(1);
(1)Kaleido Biosciences, Biology, Lexington- MA, United States;(2)Kaleido Biosciences, Computational Biology, Lexington- MA, United States;(3)Kaleido Biosciences, Chemistry, Lexington- MA, United States;(4)Kaleido Biosciences, Chemistry - Technical Operations, Lexington- MA, United States;(5)Kaleido Biosciences, Clinical Development, Lexington- MA, United States;(6)APC Microbiome Ireland, Department of Medicine, University Cork, Ireland;(7)Kaleido Biosciences, Research and Discovery, Lexington- MA, United States;
P494: A serum metabolite panel predicts Crohn’s disease relapse in patients discontinuing infliximab and continuing antimetabolite therapy: sub-analysis of the SPARE Trial.ECCO'22Year: 2022
Authors: Radford-Smith, D.(1);Satsangi, J.(2);Louis, E.(3);Laharie, D.(4);Ding, N.(5);Siegmund, B.(6);D'Haens, G.(7);Erik, H.(8);Yates, A.(9);Anthony, D.(1);Colombel, J.F.(10);Probert, F.(9);
(1)University of Oxford, Pharmacology, Oxford, United Kingdom;(2)University of Oxford, Nuffield Department of Medicine, Oxford, United Kingdom;(3)Liège University Hospital, Department of Gastroenterology, Liège, Belgium;(4)Centre Hospitalier Universitaire CHU de Bordeaux, Service d'Hépato-gastroentérologie, Bordeaux, France;(5)Imperial College London, Faculty of Medicine- Department of Surgery & Cancer, London, United Kingdom;(6)Charite Universitatsmedizin Berlin, Medical Department I, Berlin, Germany;(7)Amsterdam University Medical Centers- University of Amsterdam, Gastroenterology, Amsterdam, The Netherlands;(8)Skane University Hospital, Department of Gastroenterology, Lund, Sweden;(9)University of Oxford, Chemistry, Oxford, United Kingdom;(10)The Icahn School of Medicine at Mount Sinai, Gastroenterology, New York, United States;GETAID and the SPARE-Biocycle research group
P495: Perianal fistula closure in patients receiving ustekinumab: Results from the SEAVUE and STARDUST trialsECCO'22Year: 2022
Authors: Peyrin-Biroulet, L.(1);Panaccione, R.(2);Gasink, C.(3);Hoops, T.(3);Izanec, J.L.(3);Ma, T.(4);Nazar, M.(5);Bravata, I.(6);Lahaye, M.(7);Irving, P.M.(8);Loftus, E.V.(9);Danese, S.(10);Sands, B.E.(11);
(1)Nancy University Hospital, Gastroenterology, Vandœuvre-lès-Nancy, France;(2)University of Calgary, Gastroenterology and Hepatology, Calgary- Alberta, Canada;(3)Janssen, Immunology, Horsham, United States;(4)Janssen, Biostatistics, Horsham, United States;(5)Janssen, Immunology, Warsaw, Poland;(6)Janssen, Immunology, Milan, Italy;(7)Janssen, Biostatistics, Breda, The Netherlands;(8)Guy's and St Thomas' NHS Foundation Trust, Gastroenterology, London, United Kingdom;(9)Mayo Clinic College of Medicine, Gastroenterology and Hepatology, Minnesota, United States;(10)Vita-Salute San Raffaele University, Gastroenterology and Endoscopy, Milan, Italy;(11)Icahn School of Medicine at Mount Sinai, Dr. Henry D. Janowitz Division of Gastroenterology, New York, United States;
P496: Efficacy and safety of ustekinumab for chronic antibiotic refractory pouchitis: A Belgian open-label multicentre pilot studyECCO'22Year: 2022
Authors: Outtier, A.(1);Louis, E.(2);Dewit, O.(3);Schops, G.(1);Verstockt, B.(1);Sabino, J.(1);Vermeire, S.(1);Ferrante, M.(1);
(1)UZ Leuven, Gastroenterology, Leuven, Belgium;(2)CHU Liège- Sart Tilman, Gastroenterology, Liège, Belgium;(3)Cliniques Universitaires Saint-Luc, Gastroenterology, Bruxelles, Belgium;
P497: Early improvement in bowel wall thickness on transperineal ultrasonography predicts treatment success in active ulcerative colitisECCO'22Year: 2022
Authors: Sagami, S.(1,2);Kobayashi, T.(1);Aihara, K.(3);Umeda, M.(3);Odajima, K.(3);Morikubo, H.(1,2);Asonuma, K.(1);Miyatani, Y.(1);Fukuda, T.(1,2);Matsubayashi, M.(1,2);Kiyohara, H.(1,2);Nakano, M.(1,2);Hibi, T.(1);
(1)Kitasato University Kitasato Institute Hospital, Center for Advanced IBD Research and Treatment, Tokyo, Japan;(2)Kitasato University Kitasato Institute Hospital, Department of Gastroenterology and Hepatology, Tokyo, Japan;(3)Kitasato University Kitasato Institute Hospital, Department of Clinical Laboratory, Tokyo, Japan;
P499: Accessing ultrasonographic transmural healing in patients with Crohn’s disease after induction therapy with infliximab: should we aim for higher infliximab trough levels?ECCO'22Year: 2022
Authors: Morão, B.(1);Frias Gomes, C.(1);Revés, J.(1);Cúrdia Gonçalves, T.(2);Freitas, M.(2);Castro, F.(2);Moreira, M.J.(2);Cotter, J.(2);Pereira, F.(3);Caldeira, A.(3);Sousa, R.(3);Coelho, R.(4);Macedo, G.(4);Macedo, C.(5);Ferreira, M.(5);Glória, L.(1);Torres, J.(1);Palmela, C.(1);
(1)Hospital Beatriz Ângelo, Gastroenterology, Lisbon, Portugal;(2)Hospital da Senhora da Oliveira- Life and Health Sciences Research Institute- School of Medicine- University of Minho- Braga- ICVS/3B’s- PT Government Associate Laboratory, Gastroenterology, Guimarães/Braga, Portugal;(3)Unidade Local de Saúde de Castelo Branco- EPE- Hospital Amato Lusitano, Gastroenterology, Castelo Branco, Portugal;(4)Centro Hospitalar de São João, Gastroenterology, Porto, Portugal;(5)Centro Hospitalar Universitário de Coimbra, Gastroenterology, Coimbra, Portugal;
P501: Vedolizumab is associated with longer drug sustainability compared to infliximab in moderate-to-severe Ulcerative Colitis: a real-world cohort studyECCO'22Year: 2022
Authors: Konikoff, T.(1);Yanai, H.(1);Banai, H.(1);Avni-Biron, I.(1);Snir, Y.(1);Broitman, L.(1);Barkan, R.(1);Checholin, L.(1);Dotan, I.(1);Ollech, J.(2);
(1)Rabin Medical Center- Petah-Tikva- Israel- Sackler Faculty of Medicine- Tel Aviv University- Tel Aviv- Israel, Gastroenterology, petah tikva, Israel;(2)Rabin Medical Center- Petah-Tikva- Israel- Sackler Faculty of Medicine- Tel Aviv University- Tel Aviv- Israel, Gastroenterology, Petach Tikva, Israel;
P502: Different presentation of tuberculosis associated with anti-TNF therapy among patients with Inflammatory Bowel Disease in endemic area: observation from ChinaECCO'22Year: 2022
Authors: Ye, L.(1,2);Wu, L.(3);Tang, J.(4);Mao, R.(5);Cao, Q.(3);
(1)Xiasha Branch of Sir Run Run Shaw Hospital- School of Medicine- Zhejiang University, Department of Gastroenterology, Hangzhou, China;(2)Sir Run Run Shaw Hospital-School of Medicine-Zhejiang University, Inflammatory Bowel Disease Center, Hangzhou, China;(3)Sir Run Run Shaw Hospital- School of Medicine- Zhejiang University, Inflammatory Bowel Disease Center, Hangzhou, China;(4)The Sixth Affiliated Hospital of Sun Yat-sen Universit, Department of Gastroenterology, Guangzhou, China;(5)The First Affiliated Hospital of Sun Yat-sen University, Department of Gastroenterology, Guangzhou, China;
P503: Early TNF-antagonist maintenance therapy results in better outcomes than immunomodulators in paediatric Crohn's disease: A multi-centre prospective cohort studyECCO'22Year: 2022
Authors: Schneider, R.(1,2);Jacobson, K.(3);Huynh, H.(4);Mack, D.(5);Deslandres, C.(6);deBruyn, J.(7);El-Matary, W.(8);Otley, A.(9);Lawrence, S.(3);Wine, E.(4);Sherlock, M.(10);Critch, J.(11);Jantchou, P.(6);Rashid, M.(9);Carroll, M.(4);Bax, K.(12);Seidman, E.(13);Benchimol, E.(1,2);Ricciuto, A.(1,2);Wu, A.(1);Pullenayegum, E.(2);Walters, T.(1);Nguyen, G.(2);Griffiths, A.(1,2);Church, P.(1,2);
(1)The Hospital for Sick Children, SickKids Inflammatory Bowel Disease Centre- Department of Paediatrics, Toronto, Canada;(2)University of Toronto, Institute of Health Policy Management and Evaluation, Toronto, Canada;(3)B.C. Children’s Hospital, Division of Gastroenterology- Hepatology and Nutrition- Department of Paediatrics, Vancouver, Canada;(4)Stollery Children’s Hospital- University of Alberta, Division of Paediatric Gastroenterology and Nutrition- Department of Pediatrics, Edmonton, Canada;(5)Children’s Hospital of Eastern Ontario- University of Ottawa, Inflammatory Bowel Disease Centre- Department of Paediatrics, Ottawa, Canada;(6)Centre hospitalier universitaire Sainte-Justine, Gastroenterology- Hepatology- and Nutrition, Montreal, Canada;(7)Alberta Children’s Hospital- University of Calgary, Pediatric Gastroenterology- Hepatology & Nutrition, Calgary, Canada;(8)Winnipeg Children’s Hospital- Max Rady College of Medicine- University of Manitoba, Paediatric Gastroenterology, Winnipeg, Canada;(9)IWK Health Centre, Division of Gastroenterology- Department of Paediatrics, Halifax, Canada;(10)McMaster Children's Hospital, Division of Gastroenterology- Department of Paediatrics, Hamilton, Canada;(11)Janeway Children’s Health and Rehabilitation Centre, Division of Gastroenterology, Newfoundland, Canada;(12)Children’s Hospital London Health Sciences Centre, Division of Gastroenterology- Hepatology- and Nutrition- Department of Paediatrics, London, Canada;(13)Montreal Children's Hospital- McGill University Health Centre, Division of Gastroenterology and Nutrition, Montreal, Canada;Canadian Children Inflammatory Bowel Disease Network
P504: Prospective analysis of micronutrient status and disease course in Inflammatory Bowel DiseaseECCO'22Year: 2022
Authors: Brownson, E.(1);Saunders, J.(1);Gerasimidis, K.(2);Karafoulidou, Z.(2);Seenan, J.P.(1);Macdonald, J.(1);
(1)NHS Greater Glasgow and Clyde, Gastroenterology, Glasgow, United Kingdom;(2)University of Glasgow, School of Medicine- Dentistry and Nursing, Glasgow, United Kingdom;
P505: Smoking is associated with the development of adverse events of biological therapy in patients with Inflammatory Bowel DiseaseECCO'22Year: 2022
Authors: TheodorakiMD- MA- PhD c, E.(1);Orfanoudaki, E.(2);Foteinogiannopoulou, K.(2);Koutroubakis, I.(2);
(1)University Hospital of Heraklion, Department of Gastroenterology, Heraklion, Greece;(2)University Hospital of Heraklion- School of Medicine, Department of Gastroenterology, Heraklion, Greece;
